News | May 14, 2025
GlaxoSmithKline Pharmaceuticals posts FY25 PAT at Rs. 915 Cr
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
Carson brings with him over two decades of experience in Communications, Public Affairs, and Sustainability
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Strong topline growth driven by solid performance across key brands.
This tie-up will have no impact on any other brands of the company
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
The company has reported total income of Rs. 815.11 crores during the period ended March 31, 2023
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
GlaxoSmithKline Pharmaceuticals has reported total income of Rs. 772.71 crores during the period ended June 30, 2022
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Subscribe To Our Newsletter & Stay Updated
